Pedro Miguel Geraldes

Prix et distinctions

• (2022) Canadian Research Chair Tier II. Instituts de recherche en santé du Canada. (Distinction).
• (2016) Canadian Diabetes Association Scholar Award. Canadian Diabetes Association. (Prix).
• (2016) Chercheur boursier Junior 1 (declined since I obtained my Canada Research Chair). Fonds de recherche du Québec - Santé (FRQS). (Prix).
• (2012) Young Scientist Scholar Award. Fonds de recherche du Québec - Santé (FRQS). (Prix).
• (2010) Advanved Postdoctoral Award. Juvenile Diabetes Research Foundation. (Prix).
• (2009) Postdoctoral Award. Fonds de recherche du Québec - Santé (FRQS). (Prix).
• 2017 Young Investigator Award. FRQS CardioMetabolic, Diabetes and Obesity (CMDO) Network. (Prix).
• Chercheur boursier Junior 2 (declined since I renewed my Canada Research Chair). Fonds de recherche du Québec - Santé (FRQS). (Prix).
• New investigator Award. Arterial Hypertention Society of Quebec. (Prix).

Financement

• Subvention. (En cours d’évaluation). Candidat principal. DUSP and diabetic kidney disease. Instituts de Recherche en Santé du Canada (IRSC). Project grant. 1 218 000 $. (2023-2028)
• Subvention. (Obtenu). Candidat principal. Role of the apelinergic system in peripheral arterial disease and diabetes. Instituts de Recherche en Santé du Canada (IRSC). Project Grant. 979 200 $. (2022-2027)
• Subvention. (Obtenu). Cochercheur. The Developmental Origins of Pediatric Type 2 Diabetes and Early Renal Dysfunction. Instituts de Recherche en Santé du Canada (IRSC). Team Grant: Diabetes Mechanisms and Translational Solutions. 1 996 555 $. (2022-2027)
• Subvention. (Obtenu). Chercheur principal. Center of Excellence of the Université de Sherbrooke in Diabetes, Obesity and Cardiovascular Complications (CEUSDOCC). Université de Sherbrooke. Center of excellence program. 163 000 $. (2020-2026)
• Subvention. (Obtenu). Candidat principal. Electron microscopy platform to study kidney pathologies, chronic pain and nanoparticule structure. Fondation Canadienne pour l'Innovation (FCI). John-R.-Evans Leader Funds. 1 014 000 $. (2022-2024)
• Subvention. (Obtenu). Chercheur principal. Phosphatases and mechanisms of poor collateral vessel formation in diabetes. Instituts de Recherche en Santé du Canada (IRSC). Project Grant. 753 526 $. (2018-2023)
• Chaire de recherche. (Terminé). Chercheur principal. Canadian Research Chair in Diabetes and Vascular Complications.. (2012-2022)
• Subvention. (Terminé). Chercheur principal. Mechanisms of insulin resistance in podocytes and diabetic nephropathy. Instituts de Recherche en Santé du Canada (IRSC). Project grant. 677 025 $. (2017-2022)
• Subvention. (Terminé). Chercheur principal. Evaluation of SHP-1 expression in podocyturia of diabetic patients.. Fondation Diabète Brome-Missisquoi. Biomedical Grant. 50 000 $. (2016-2019)
• Subvention. (Terminé). Candidat principal. Role of IGFBP-2 on podocyte injury and type 2 diabetic nephropathy. CMDO network FRQ-S. Inter center project grant. 40 000 $. (2018-2019)
• Subvention. (Terminé). Chercheur principal. Role of PKC isoform in poor collateral vessel formation and angiogenic response in diabetes.. (2013-2018)
• Subvention. (Terminé). Chercheur principal. Mechanisms of diabetes-induced insulin resistance in podocytes. (2015-2017)
• Subvention. (Terminé). Chercheur principal. Role of SHP-1 in podocyte function and type 1 diabetic nephropathy. (2015-2016)
• Subvention. (Terminé). Chercheur principal. Mechanisms of podocyte injury in type 1 and type 2 diabetic kidney disease.. (2015-2016)
• Subvention. (Terminé). Chercheur principal. Live-cell perfusion imaging to study vascular complications of diabetes. Fondation Canadienne pour l'Innovation (FCI). John-R.-Evans Leader Funds. 230 437 $. (2014-2014)
• Subvention. (Terminé). Chercheur principal. Mechanisms of glycemic memory in diabetic nephropathy. (2013-2014)
• Subvention. (Terminé). Chercheur principal. Insulin actions in podocyte injury associated to diabetic nephropathy. (2013-2014)
• Subvention. (Terminé). Chercheur principal. Role of PKC delta in PDGF and VEGF inhibition causing poor collateral vessel formation in diabetes.. (2010-2013)
• Subvention. (Terminé). Chercheur principal. Role of PKC and SHP-1 in podocyte apoptosis and diabetic nephropathy. (2010-2012)

Publications

Articles de revue

• Lizotte, F*; Rousseau, M*; Denhez, B*; Levesque, D; Guay, A; Higgins, S; Sabbagh, R; Boisvert, F-M; Cote, A-M; Geraldes, P. (2022). Deletion of SHP-1 restores SUMOylation of podocin and reverses the progression of diabetic kidney disease. JASN 1 1-35. (Article soumis).
• Lizotte, F; Robillard, S*; Lavoie, N*; Rousseau, M*; Denhez, B*; Moreau, J; Higgins, S; Sabbagh, R; Cote, A-M; Geraldes, P. (2022). Enhanced SHP-1 expression in podocyturia is associated with kidney dysfunction in patients with diabetes. Kidney 360 1 1-24. (Article sous presse).
• Rousseau, M*; Denhez, B*; Spino, C*; Guay, A, Lizotte, F; Cote, A-M; Durger, D; Geraldes, P. (2022). Reduction of DUSP4 contributes to podocytes oxidative stress, insulin resistance and diabetic nephropathy. Biochemical and Biophysical Research Communications 624 127-133. (Article publié).
• Hamelin Morrissette, J*; Tremblay, D*; Marcotte-Chénard, A; Lizotte, F; Brunet, MA; Laurent, B; Riesco, E; Geraldes, P. (2022). Transcriptomic Modulation in Response to High-IntensityInterval Training in Monocytes of Older Women with Type 2 Diabetes. Eur Applied Physiology 1 (Feb 19), 1-11. (Article publié).
• Croteau, L*; Mercier, C*; Fafard-Couture, E*; Nadeau, A*; Robillard, S*; Breton, V*; Guay, A; Lizotte, F; Despatis, M-A; Geraldes, P. (2021). Diabetes and Vascular Disease Research 18 (2), 1479164121999033. (Article publié).
• Mercier, C*; Brazeau, T*; Lamoureux, J*; Boisvert, E*; Robillard, S*; Breton, V*; Paré, M*; Guay, A; Lizotte, F; Despatis, M-A; Geraldes, P. (2021). Diabetes impaired ischemia-induced PDGF signaling actions and vessel formation through the activation of Scr homology 2-containing phosphatase-1. ATVB 41 (9), 2469-82. (Article publié).
• Perazza, LR; Mitchell, P; Lizotte, F; Jensen, B; St-Pierre, P; Trottier, J; Barbier, O; Mathieu, P; Geraldes, P; Marette, A. (2021). Fish oil replacement prevents, while DHA-derivedprotectin DX mitigates end-stage-renal-disease in atherosclerotic diabetic mice. FASEB J 35 (5), e21559. (Article publié).
• Mercier, C*; Rousseau, M*; Geraldes, P. (2021). Growth factor deregulation and emerging role of phosphatases in diabetic peripheral artery disease. Frontiers in Cardiovascular Medicine 7 (619612), 1-13. (Article publié).
• Robillard, S*; Mercier, C*; Breton, V*; Paquin-Veillette, J*; Guay, A; Lizotte, L; Geraldes, P. (2020). Ablation of AT2 receptor prevents eNOS glutathionylation and nitration in ischemic abductor muscle of diabetic mice. Diabetes Vascular Disease Research 17 (1), 1479164119883978. DOI. (Article publié).
• Denhez, B*; Rousseau, M*; Spino, C*; Dancosst, D-A*; Dumas, M-E*; Guay, A; Lizotte, F; Geraldes, P. (2020). Saturated fatty acids induce insulin resistance in podocytes through inhibition of IRS1 via activation of both IKKβ and mTORC1. Scientific Reports 10 (1), 21628. (Article publié).
• Lacroix M., Lizotte F., Hivert M-F., Geraldes P²., Perron P². ²Co-Senior Authors. (2019). Calcifediol decreases interleukin-6 secretion by cultured human trophoblasts from GDM pregnancies. Journal of the Endocrine Society 3 (11), 2165-78. DOI. (Article publié).
• Denhez, B*; Rousseau, M*; Dancosst, D-A*; Lizotte, F; Guay, A; Auger-Messier, M; Côté, A-M; Geraldes, P. (2019). Diabetes-induced DUSP4 reduction promotes podocyte dysfunction and progression of diabetic nephropathy. Diabetes 68 (5), 1026-1039. (Article publié).
• Quiroga, DT; Miquet, JG; Gonzalez, L; Sotelo, AI; Muñoz, MC; Geraldes, PM; Giani, JF; Dominici, FP. (2019). Mice Lacking angiotensin type 2 receptor exhibit a sex-specific attenuation of insulin sensitivity. Mollecular and Cellular Endocrinology 498 110587. DOI. (Article publié).
• Barrière, DA; Noll, C; Roussy, G; Lizotte, F*; Kessai, A; Kirby, K; Belleville, K; Beaudet, N; Longpre, J-M; Carpentier, AC; Geraldes, P; Sarret, P. (2018). Combination of high-fat/high-fructose diet and low-dose streptozotocinto model long-term type-2 diabetes complications. Scientific Report 8 (1), 424. (Article publié).
• Geraldes, P. (2018). Protein Phosphatase and Podocyte Function. Current Opinion in hypertension and nephropathy 27 (1), 49-55. (Article publié).
• Paquin-Veillette, J*; Lizotte, F; Robillard, S*; Béland, R*; Breton, M-A*; Despatie, M-A; Geraldes, P. (2017). Deletion of AT2 receptor prevents SHP-1 causing VEGF inhibition and improves blood flow reperfusion in diabetic ischemic hindlimb. ATVB 37 (12), 2291-2300. (Article publié).
• Denhez, B*; Geraldes, P. (2017). Regulation of Nephrin Phosphorylation in Diabetes and Chronic Kidney Injury. Adv Exp Med Biol 966 149-161. (Article publié).
• Lizotte, F*; Denhez, B*; Guay, A; Gévry, N; Côté, AM; Geraldes, P. (2016). Persistent insulin resistance in podocytes caused by epigenetic changes of SHP-1 in diabetes. Diabetes 65 (12), 3705-17. (Article publié).
• Denhez, D*; Lizotte, F*; Guimond, M-O; Jones, N; Takano, T; Geraldes, P. (2015). Increased SHP-1 expression by high glucose levels reduced nephrin phosphorylation in podocytes. The Journal of biological chemistry 390 (1), 350-8. (Article publié).
• Durpès, M-C*; Morin, C*; Paquin-Veillette, J*; Béland, R*; Paré, M*; Guimond, M-O; Rekhter, M; King, GL; Geraldes, P. (2015). PKC beta activation inhibits interleukin-18 binding protein causing endothelial dysfunction and accelerated diabetic atherosclerosis. Cardiovascular Research 106 (2), 303-13. (Article publié).
• Drapeau N.*, Lizotte F.*, Denhez B.*, Guay A., Kennedy CR., Geraldes P. (2013). Expression of SHP-1 induced by hyperglycemia prevents insulin actions in podocytes. American journal of physiology. Endocrinology and metabolism 304 (11), E1188-98. (Article accepté).
• Lizotte F.*, Paré M.*, Denhez B.*, Leitges M., Guay A., Geraldes P. (2013). PKCdelta Impaired Vessel Formation and Angiogenic Factor Expression in Diabetic Ischemic Limbs. Diabetes 62 (8), 2948-57. (Article accepté).
• Mima A., Kitada M., Geraldes P., Li Q., Matsumoto M., Mizutani K., Qi W., Li C., Leitges M., Rask-Madsen C., King GL. (2012). Glomerular VEGF resistance induced by PKC?/SHP-1 activation and contribution to diabetic nephropathy. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 26 (7), 2963-74. (Article accepté).
• Mima A., Hiraoka-Yamomoto J., Li Q., Kitada M., Li C., Geraldes P., Matsumoto M., Mizutani K., Park K., Cahill C., Nishikawa S., Rask-Madsen C., King GL. (2012). Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKC? activation in diabetes. Diabetes 61 (11), 2967-79. (Article accepté).
• Mima A., Ohshiro Y., Kitada M., Matsumoto M., Geraldes P., Li C., Li Q., White GS., Cahill C., Rask-Madsen C., King GL. (2011). Glomerular-specific protein kinase C-?-induced insulin receptor substrate-1 dysfunction and insulin resistance in rat models of diabetes and obesity. Kidney international 79 (8), 883-96. (Article accepté).
• Geraldes P , King GL. (2010). Activation of protein kinase C isoforms and its impact on diabetic complications. Circulation research 106 (8), 1319-31.
• Rask-Madsen C , Li Q , Freund B , Feather D , Abramov R , Wu IH , Chen K , Yamamoto-Hiraoka J , Goldenbogen J , Sotiropoulos KB , Clermont A , Geraldes P , Dall'Osso C , Wagers AJ , Huang PL , Rekhter M , Scalia R ,. (2010). Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice. Cell metabolism 11 (5), 379-89. (Article accepté).
• Geraldes P , Hiraoka-Yamamoto J , Matsumoto M , Clermont A , Leitges M , Marette A , Aiello LP , Kern TS , King GL. (2009). Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nature medicine 15 (11), 1298-306.
• Kondo T , El Khattabi I , Nishimura W , Laybutt DR , Geraldes P , Shah S , King G , Bonner-Weir S , Weir G , Sharma A. (2009). p38 MAPK is a major regulator of MafA protein stability under oxidative stress. Molecular endocrinology (Baltimore, Md.) 23 (8), 1287-90.
• Geraldes P , Geoffroy P , Cloutier I , Sirois MG , Tanguay JF. (2008). Local delivery of 17-beta-estradiol modulates collagen content in coronary porcine arteries after PTCA and stent implantation. Journal of vascular research 45 (6), 503-11.
• Geraldes P , Yagi K , Ohshiro Y , He Z , Maeno Y , Yamamoto-Hiraoka J , Rask-Madsen C , Chung SW , Perrella MA , King GL. (2008). Selective regulation of heme oxygenase-1 expression and function by insulin through IRS1/phosphoinositide 3-kinase/Akt-2 pathway. The Journal of biological chemistry 283 (49), 34327-36.
• Geraldes P , Yamagata M , Rook SL , Sassa Y , Ma RC , Clermont A , Gao B , Aiello LP , Feener EP , King GL. (2007). Glypican 4, a membrane binding protein for bactericidal/permeability-increasing protein signaling pathways in retinal pigment epithelial cells. Investigative ophthalmology & visual science 48 (12), 5750-55.
• Geraldes P , Gosselin H , Tanguay JF , Clément R , Calderone A. (2007). Tamoxifen treatment of myocardial infarcted female rats exacerbates scar formation. Pflügers Archiv : European journal of physiology 454 (3), 385-93.
• Yamagata M , Rook SL , Sassa Y , Ma RC , Geraldes P , Goddard L , Clermont A , Gao B , Salti H , Gundel R , White M , Feener EP , Aiello LP , King GL. (2006). Bactericidal/permeability-increasing protein's signaling pathways and its retinal trophic and anti-angiogenic effects. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20 (12), 2058-67.
• Geraldes P , Gagnon S , Hadjadj S , Merhi Y , Sirois MG , Cloutier I , Tanguay JF. (2006). Estradiol blocks the induction of CD40 and CD40L expression on endothelial cells and prevents neutrophil adhesion: an ERalpha-mediated pathway. Cardiovascular research 71 (3), 566-73.
• Gagnon C , Legault F , Geraldes P , Tanguay JF , Lambert C. (2004). Diverse effects of Ace inhibitors and angiotensin II receptor antagonists on prevention of cardiac hypertrophy and collagen distribution in spontaneously hypertensive rats. International journal of cardiology 97 (3), 373-81.
• Geraldes P , Sirois MG , Tanguay JF. (2003). Specific contribution of estrogen receptors on mitogen-activated protein kinase pathways and vascular cell activation. Circulation research 93 (5), 399-405.
• Geraldes P , Sirois MG , Bernatchez PN , Tanguay JF. (2002). Estrogen regulation of endothelial and smooth muscle cell migration and proliferation: role of p38 and p42/44 mitogen-activated protein kinase. Arteriosclerosis, thrombosis, and vascular biology 22 (10), 1585-90.

Articles de conférence

• Geraldes, P.; Nadeau, A.*; Mercier, C.*; Lizotte, S.; Despatis, M-A. (2022). Deletion Of Shp-1 Prevents Diabetes-induced Endothelial Cell Senescence And Restores Blood Flow Reperfusion Following Ischemia. Vascular Discovery: From Genes to Medicine 2022 Scientific Sessions. (Article accepté).
• Robillard, S.*; Marsault, E.; Auger-Messier, M.; Geraldes, P. (2021). The apelinergic system improves angiogenesis and blood flow reperfusion in diabetic mouse model of lower limb ischemia. American Diabetes Association. (Article accepté).
• Mercier, C.*; Brazeau, T.*; Robillard, S.*; Guay, A.; Lizotte, F.; Geraldes, P. (2020). Deletion of SHP-1 in smooth muscle cells prevented diabetes-induced impaired collateral vessel formation in ischemic muscle. Canadian Vascular & Lipid Virtual Summit 2020. (Article accepté).
• Mercier, C.*; Robillard, S.*; Breton, V.*; Guay, A.; Lizotte, F.; Geraldes, P. (2019). Ablation of AT2 receptor prevents endothelial nitric oxide synthase uncoupling in ischaemic abductor muscle of diabetic mice. American Heart Association. (Article accepté).
• Rousseau, M.*; Dancosst, D-A.*; Denhez, B.*; Guay, A.; Lizotte, F.; Geraldes, P. (2019). Hyperglycemia reduced DUSP4 expression leads to JNK MAPK activation and increased NOX4 expression in podocytes and diabetic nephropathy. American Society of Nephrology. (Article accepté).
• Dancosst, D-A.*; Rousseau, M.*; Lizotte, F.; McGavock, J.; Picard, F.; Geraldes, P. (2019). Role of Insulin-like Growth Factor Binding Protein 2 on Podocyte Function and Diabetic Nephropathy. Diabetes Canada Professional Conference and Annual Meeting. (Article accepté).
• Geraldes, P.; Lizotte, F.; Moreau, J.; Higgins, S.; Sabbagh, R.; Coté, A-M. (2019). SHP-1 as a marker of podocyturia and diabetes kidney disease. European Association for the Study of Diabetes. (Article accepté).
• Rousseau, M.*; Denhez, B.*; Lizotte, F.; Geraldes, P. (2018). PKC-δ Reduced DUSP4 Expression Causing NOX4 and Progressive Diabetic Nephropathy. American Society of Nephrology. (Article accepté).
• Geraldes, P.; Lizotte, F.; Despatis, M-A. (2018). Specific Deletion of PKC delta in Endothelial Cells Restores VEGF Action in Diabetes. American Diabetes Association. (Article accepté).
• Lizotte, F.*; Geraldes, P. (2018). Specific deletion of SHP-1 in Smooth Muscle Cells Restores PDGF Action in Diabetes. Vascular Discovery - ATVB. (Article accepté).
• Lizotte, F.; Geraldes, P. (2017). Deletion of SHP-1 Specifically in Smooth Muscle Cells Restores PDGF Action in Diabetes. Diabetes Canada Professional Conference and Annual Meeting. (Article accepté).
• Denhez, B.*; Rousseau, M.*; Lizotte, F.*, Auger-Messier, M.; Côté, A-M.; Geraldes, P. (2017). Loss of DUSP4 promotes insulin resistance in podocytes through JNK activativation. American Society of Nephrology. (Article accepté).
• Dumas, M-E.*; Denhez, B.*; Lizotte, F.; Geraldes, P. (2017). Mechanisms of Insulin Resistance induced by FFA inRenal Podocytes Leading to Diabetic Nephropathy. American Diabetes Association. (Article accepté).
• Robillard, S.*; Lizotte, F.; Guay, A.; Geraldes, P. (2017). Reduction of DUSP4 Exacerbates Blood Flow Reduction in Diabetes. Diabetes Canada Professional Conference and Annual Meeting. (Article accepté).
• Denhez, B.*; Lizotte, F.*; Guay, A.; Geraldes, P. (2016). Role of DUPS4 in kidney complications of diabetes. Canadian Diabetes Association/CSEM annual professional conference. (Article publié).
• Paquin-Veillette, J.*; Guay, A.; Geraldes, P. (2015). Deletion of AT2 Receptor Prevents SHP-1 Expression and Improves Blood Flow in Diabetic Ischemic Hindlimb. American Heart Association. (Article publié).
• Lizotte, F.*; Denhez, B.*; Guay, A.; Geraldes, P. (2015). Deletion of SHP-1 in Podocytes Prevents Diabetic Nephropathy. American Society of Nephrology Kidney Week. (Article publié).
• Lizotte, F.*; Denhez, B.*; Guay, A.; Geraldes, P. (2015). Hyperglycemic Memory in DN: Effects of Epigenetic Changes of SHP-1 in Podocytes. American Society of Nephrology Kidney Week. (Article publié).
• Denhez, B.*; Lizotte, F.*; Guay, A.; Geraldes, P. (2015). Role of DUPS4 inDiabetic Nephropathy. American Society of Nephrology Kidney Week. (Article publié).
• Pare M., Guimond M-O., Geraldes P. (2014). Activationby Hyperglycemia Inhibits PDGF’s Pro-Angiogenic Effects in Hypoxic SmoothMuscle Cells. Canadian Diabetes Association/CSEM annual professional conference. (Article publié).
• Lizotte F., Denhez B., Guimond M-O., Geraldes P. (2014). Hyperglycemic memory indiabetes nephropathy: potential role of SHP-1. Canadian Diabetes Association/CSEM annual professional conference. (Article publié).
• Lizotte F., Denhez B., Kennedy C.R., Guimond M-O., Geraldes P. (2013). Glycemic Memory in Diabetes Nephropathy, Potential Role Of SHP-1. American Society of Nephrology Kidney Week. (Article publié).
• Denhez B., Lizotte F., Kennedy C.R., Guimond M-O., Geraldes P. (2013). Inhibition of Nephrin Signaling by SHP-1 in Diabetic Nephropathy. American Society of Nephrology Kidney Week. (Article publié).
• Denhez B., Lizotte F., Guimond M-O., Geraldes P. (2013). New Mechanism for Podocyte Dysfunction: Regulation of Nephrin by SHP-1. Vascular 2013. (Article publié).
• Geraldes P. (2013). Targeting Protein Kinase C in the vessel wall: newperspectives. Cardiometabolic Risk and Vascular Diseases Symposium: European Society of Cardiology. (Article publié).
• Durpes M-C., Morin C., Guimond M-O. Geraldes P. (2013). The dysregulation of Interleukin-18 pathway: a potentiallink between hyperglycemia and the accelerated atherosclerosis in diabetes. Vascular 2013. (Article publié).
• Durpes M-C., Geraldes P. (2013). The dysregulation of Interleukin-18 pathway: a potential link between hyperglycemia and the accelerated atherosclerosis in diabetes. European Atherosclerosis Society. (Article publié).
• Drapeau N., Lizotte F., Geraldes P. (2012). Hyperglycemia-induced SHP-1 causes insulinresistance in podocytes. American Diabetes Association conference. (Article publié).
• Drapeau N., Lizotte F., Geraldes P. (2012). Hyperglycemia-induced SHP-1 expression leads toinhibition of insulin actions and podocyte apoptosis. Canadian Nephrology Society. (Article publié).
• Pare M., Guay A., Geraldes P. (2012). PKC Activation RegulatesInsulin Action in Vascular Smooth Muscle Cells: Potential Mechanism for PoorCollateral Vessel Formation in Diabetes. Canadian Diabetes Association/CSEM annual professional conference. (Article publié).
• Mima A., Munehiro K., Geraldes P., Li Q., Qi W., Mizutani K., Rask-Madsen C., King G.L. (2011). Hyperglycemia Induced Inactivation of VEGF byPKC?/SHP-1: A Cause for Podocyte Apoptosis in Diabectic Nephropathy. American Diabetes Association conference. (Article publié).
• Rousseau, M.*; Lizotte, F.; Geraldes, P. Reduction of DUSP4 enhances macrophageinfiltration and contribution to renal fibrosis. American Society of Nephrology.

Propriétés intellectuelles

Brevets

• Methods of Modulating Metabolic Memory. 10276-112W01. États-Unis d'Amérique. (Délivré).

Autres contributions

Cours enseignés

• (2012-04-11 à 2012-04-11).Université de Sherbrooke. Canada. (2CR).
• (2012-01-12 à 2012-05-23).Université de Sherbrooke. Canada. (2CR).

Gestion d'évènements

• Organizer. Scientific Day of the Diabetes, Obesity and Cardiovascular Complications (DOCC) team group. (Séminaire).

Présentations

• (2023). Angiotensine receptor type 2 and capelin receptor in peripheral arterial diseases. Advanced Angiotensin Therapeutics Network. Vancouver, Canada
• (2023). Diabetic kidney disease and protecting factors. Quebec Arterial Hypertensive Society. Québec, Canada
• (2022). SHP-1 in endothelial cell senescence in diabetes. Vascular Discovery: From Genes to Medicine 2022. Seattle, États-Unis d'Amérique
• (2021). Peripheral arterial disease in diabetes: where do we stand?. Diabetes Canada Annual Conference. Canada
• (2021). Phosphatase, insulin resistance and chronic kidney disease. MUCH endocrin conference. Montreal, Canada
• (2021). Phosphatases, insulin resistance and diabetic nephropathy. M3K - Canadian Kidney Conference. Canada
• (2020). New treatment strategies to prevent peripheral arterial disease in diabetes. Canadian Vascular and Lipid Summit. Virtual, Canada
• (2019). Role of phosphatase in peripheral arterial and chronic kidney diseases in diabetes. CardioMetabolic, Diabetes and Obesity Annual Meeting. Offord, Canada
• (2019). The role of phosphatases in diabetic renal disease. HMR Seminar Series. Montreal, Canada
• (2017). Mechanisms of insulin resistance in podocytes and diabetic nephropathy. CRCHUM - MUHC Nephrology Conference. Canada
• (2017). Protecting factor inhibition and vascular complications of diabetes. Indiana University School of Public Health-Bloomington. États-Unis d'Amérique
• (2016). Essentials for Preparing a Career in Diabetes and Endocrine Research. CDA/CSEM Professional Conference. Ottawa, Canada
• (2016). Vascular complication of diabetes. Signalisation Québec 2016. Trois-Rivières, Canada
• (2013). Diabetes and cardiovascular complications: the quest to find new markers. Conference series - Montreal Heart Institute. Montreal, Canada
• (2013). Glycemic memory in diabetic nephropathy: the quest to find new mechanisms. CHUM-MUHC Nephrology Conference. Montreal, Canada
• (2013). Inhibition of the Protecting Factors: New Mechanism of Vascular Complications in Diabetes. IRCM Cardiometabolite Disease Seminar Series. MONTREAL, Canada
• (2013). Insulin regulation in podocytes and diabetic nephropathy. University of Toronto CityWide Endocrine Rounds. Toronto, Canada
• (2013). New Mechanisms for metabolic legacy effect in diabetic nephropathy. Kidney Research Centre (KRC) Journal Club rounds. Ottawa, Canada
• (2013). Targeting Protein Kinase C in the vessel wall: new perspectives. 2e symposium Cardiometabolic Risk and Vascular Diseases – from Mechanisms to Treatment. Rome, Italie
• (2013). Vascular complications of diabetes: why there is no treatment yet?. BioMed Research Center. Montreal, Canada
• (2011). Diabetes and Vascular Complications: Beyond Oxidative Stress. Endocrinology/Nutrition/Renal Diseases. Canada
• (2010). Hyperglycemia-induced apoptosis – a NF-?B independent pathway. Signalisation Quebec 2010. Offord, Canada